Newsroom

December 2019

• Press release Dec 19, 2019

  AveXis Community Statement on Global Managed Access Program for AVXS-101

  Dear SMA Community, Since its U.S. approval, AveXis has had increasing demand from families outside of the U.S. for access to AVXS-101. While we are pursuing registration in close to three dozen…
• 
  Story Dec 19, 2019 People and Culture

  Parental Leave at Novartis: Michael's story

  At Novartis, we celebrate life and recognize moments that matter. Michael Wieser shares his experience of parental leave and becoming a father of two.

• Ad hoc release Dec 16, 2019

  Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma

  Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across…
• Press release Dec 13, 2019

  Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD

  In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-…
• Press release Dec 12, 2019

  Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3

  MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30…
• Press release Dec 09, 2019

  Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

  Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3  Fewer known CAR-T cell therapy…
• Featured News Dec 09, 2019

  Uncovering profound and under-reported effects on people living with sickle cell disease

  Results of the Sickle Cell World Assessment Survey (SWAY) highlight the impact this debilitating disease has on patients and their families.
• Press release Dec 09, 2019

  Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients

  Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell disease and a pattern of not seeking care despite potentially life-…
• 
  Story Dec 09, 2019 Discovery

  A decades-long journey in blood cancer research

  Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

• Press release Dec 06, 2019

  Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy

  Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak…
• Featured News Dec 05, 2019

  Novartis R&D Day

  Novartis shares progress in advancing its industry-leading R&D pipeline. We are uniquely positioned to deliver transformational treatments through our scale, focus on innovative medicines, diverse range of therapeutic areas and exposure to cutting-edge platforms.

• Press release Dec 05, 2019

  Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day

  Uniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms60 projects in Phase 2 pipeline with 10+ advancing…